Incyte (INCY) Revenue (2010 - 2026)
Incyte's (INCY) quarterly Revenue came in at $1.7 billion in Q2 2026, up 37.72% YoY from $1.2 billion in Q2 2025, and up 31.54% on a QoQ basis from $1.3 billion in Q1 2026.
Analysis
Incyte (INCY) Revenue (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Revenue data on file, last reported at $1.7 billion in Q2 2026.
- Quarterly Revenue rose 37.72% year-over-year to $1.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.8 billion (up 26.93% YoY) and the FY2025 annual result came in at $5.1 billion, up 21.22% from the prior year.
- Revenue grew to $1.7 billion in Q2 2026, from $1.3 billion in the prior quarter.
- In the past five years, Revenue ranged from a high of $1.7 billion in Q2 2026 to a low of $733.2 million in Q1 2022.
- A 5-year average of $1.1 billion and a median of $1.0 billion in 2023 frame the typical range for Revenue.
- Annual changes were most pronounced in 2022 — Revenue climbed 1.27% — and 2026, when it soared 37.72%.
- Tracing INCY's Revenue over 5 years: stood at $926.7 million in 2022, then grew by 9.35% to $1.0 billion in 2023, then climbed by 16.32% to $1.2 billion in 2024, then grew by 27.84% to $1.5 billion in 2025, then increased by 11.1% to $1.7 billion in 2026.
- The last three Revenue figures came in at $1.7 billion (Q2 2026), $1.3 billion (Q1 2026), and $1.5 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.68 Bn | 131.82 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.68 Bn | 77.68 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 63.67 Bn | 58.48 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 57.02 Bn | 51.88 Bn | 52.00 Mn | 145.00 Mn |
| 5 | Revolution Medicines | 43.83 Bn | 43.83 Bn | - | - |
| 6 | BeOne Medicines | 39.97 Bn | 34.87 Bn | 1.53 Bn | 1.71 Bn |
| 7 | Alnylam Pharmaceuticals | 35.23 Bn | 31.93 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Royalty Pharma | 28.56 Bn | 27.72 Bn | - | 674.14 Mn |
| 9 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Incyte | 25.49 Bn | 20.95 Bn | 1.57 Bn | 1.67 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.67 Bn |
| Mar 31, 2026 | 1.27 Bn |
| Dec 31, 2025 | 1.51 Bn |
| Sep 30, 2025 | 1.37 Bn |
| Jun 30, 2025 | 1.22 Bn |
| Mar 31, 2025 | 1.05 Bn |
| Dec 31, 2024 | 1.18 Bn |
| Sep 30, 2024 | 1.14 Bn |
| Jun 30, 2024 | 1.04 Bn |
| Mar 31, 2024 | 880.89 Mn |
| Dec 31, 2023 | 1.01 Bn |
| Sep 30, 2023 | 919.03 Mn |
| Jun 30, 2023 | 954.61 Mn |
| Mar 31, 2023 | 808.67 Mn |
| Dec 31, 2022 | 926.70 Mn |
| Sep 30, 2022 | 823.30 Mn |
| Jun 30, 2022 | 911.40 Mn |
| Mar 31, 2022 | 733.24 Mn |
| Dec 31, 2021 | 862.85 Mn |
| Sep 30, 2021 | 812.99 Mn |